WO2022263601A1 - Microcompartiments cellulaires de grande taille comprenant plusieurs cystes - Google Patents
Microcompartiments cellulaires de grande taille comprenant plusieurs cystes Download PDFInfo
- Publication number
- WO2022263601A1 WO2022263601A1 PCT/EP2022/066498 EP2022066498W WO2022263601A1 WO 2022263601 A1 WO2022263601 A1 WO 2022263601A1 EP 2022066498 W EP2022066498 W EP 2022066498W WO 2022263601 A1 WO2022263601 A1 WO 2022263601A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- microcompartment
- microcompartments
- cell
- hydrogel
- Prior art date
Links
- 208000031513 cyst Diseases 0.000 title claims abstract description 86
- 230000001413 cellular effect Effects 0.000 title claims abstract description 17
- 239000000017 hydrogel Substances 0.000 claims abstract description 56
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 54
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 53
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 53
- 206010011732 Cyst Diseases 0.000 claims abstract description 39
- 241000282414 Homo sapiens Species 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 210000005260 human cell Anatomy 0.000 claims abstract description 10
- 210000004102 animal cell Anatomy 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 271
- 238000005538 encapsulation Methods 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 239000001963 growth medium Substances 0.000 claims description 37
- 230000001120 cytoprotective effect Effects 0.000 claims description 20
- 230000003321 amplification Effects 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 235000010443 alginic acid Nutrition 0.000 claims description 14
- 229920000615 alginic acid Polymers 0.000 claims description 14
- 230000032823 cell division Effects 0.000 claims description 14
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 13
- 229940072056 alginate Drugs 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 9
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 7
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- 210000002919 epithelial cell Anatomy 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 5
- 210000000981 epithelium Anatomy 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- 210000001174 endocardium Anatomy 0.000 claims description 3
- 210000001703 glandular epithelial cell Anatomy 0.000 claims description 3
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 3
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000010410 layer Substances 0.000 description 66
- 239000002775 capsule Substances 0.000 description 33
- 210000000130 stem cell Anatomy 0.000 description 17
- 210000001778 pluripotent stem cell Anatomy 0.000 description 16
- 230000012010 growth Effects 0.000 description 10
- 230000008672 reprogramming Effects 0.000 description 10
- 230000035772 mutation Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 108091007065 BIRCs Proteins 0.000 description 7
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 7
- 102000001253 Protein Kinase Human genes 0.000 description 6
- 108060006633 protein kinase Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 3
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- -1 laminins Proteins 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000004401 podocalyxin Human genes 0.000 description 3
- 108090000917 podocalyxin Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000282341 Mustela putorius furo Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000000158 apoptosis inhibitor Substances 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008003 autocrine effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 238000001001 laser micro-dissection Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- DOBKQCZBPPCLEG-UHFFFAOYSA-N n-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/34—Internal compartments or partitions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/16—Particles; Beads; Granular material; Encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2539/00—Supports and/or coatings for cell culture characterised by properties
Definitions
- ⁇ culture medium within the meaning of the invention is meant a culture medium animated by internal movements.
- the internal part 14 of the microcompartment according to the invention comprises at least two cysts, each cyst being formed by at least one layer of cells 18 organized in three dimensions around a lumen 20.
- an isotonic intermediate solution preferably an isotonic solution not containing a divalent cation such as Ca 2+ Mg 2+ to avoid cross-linking of the hydrogel too early in the injector, such as for example a sorbitol solution, the solution from step b) comprising cells, culture medium and the extracellular matrix.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Sustainable Development (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Clinical Laboratory Science (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3222350A CA3222350A1 (fr) | 2021-06-16 | 2022-06-16 | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes |
JP2023576139A JP2024521447A (ja) | 2021-06-16 | 2022-06-16 | 複数の嚢胞を含む大型細胞微小区画 |
IL309237A IL309237A (en) | 2021-06-16 | 2022-06-16 | Large cellular microclasses that include a large number of cysts |
US18/270,931 US20240060025A1 (en) | 2021-06-16 | 2022-06-16 | Large cellular microcompartments comprising a plurality of cysts |
KR1020237043407A KR20240032739A (ko) | 2021-06-16 | 2022-06-16 | 복수의 낭종을 포함하는 큰 세포 미세구획 |
AU2022295088A AU2022295088A1 (en) | 2021-06-16 | 2022-06-16 | Large cellular microcompartments comprising a plurality of cysts |
EP22735136.8A EP4355854A1 (fr) | 2021-06-16 | 2022-06-16 | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2106403A FR3124193B3 (fr) | 2021-06-16 | 2021-06-16 | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes |
FRFR2106403 | 2021-06-16 | ||
FR2114709A FR3124192A1 (fr) | 2021-06-16 | 2021-12-31 | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes |
FRFR2114709 | 2021-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022263601A1 true WO2022263601A1 (fr) | 2022-12-22 |
Family
ID=82319893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/066498 WO2022263601A1 (fr) | 2021-06-16 | 2022-06-16 | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240060025A1 (fr) |
EP (1) | EP4355854A1 (fr) |
JP (1) | JP2024521447A (fr) |
KR (1) | KR20240032739A (fr) |
AU (1) | AU2022295088A1 (fr) |
CA (1) | CA3222350A1 (fr) |
IL (1) | IL309237A (fr) |
WO (1) | WO2022263601A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023235884A1 (fr) | 2022-06-03 | 2023-12-07 | Flagship Pioneering Innovations Vi, Llc | Compositions et méthodes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010105311A1 (fr) | 2009-03-20 | 2010-09-23 | Angioblast Systems, Inc. | Production de cellules pluripotentes reprogrammées |
WO2018096277A1 (fr) | 2016-11-23 | 2018-05-31 | Universite de Bordeaux | Microcompartiment cellulaire et procédés de préparation |
US20200002681A1 (en) * | 2017-03-09 | 2020-01-02 | Universite de Bordeaux | Hollow cellular microfibre and method for producing such a hollow cellular microfibre |
WO2021028456A1 (fr) * | 2019-08-12 | 2021-02-18 | Treefrog Therapeutics | Unite tridimensionnelle creuse de tissu retinien et utilisation dans le traitement des retinopathies |
-
2022
- 2022-06-16 WO PCT/EP2022/066498 patent/WO2022263601A1/fr active Application Filing
- 2022-06-16 US US18/270,931 patent/US20240060025A1/en active Pending
- 2022-06-16 JP JP2023576139A patent/JP2024521447A/ja active Pending
- 2022-06-16 EP EP22735136.8A patent/EP4355854A1/fr active Pending
- 2022-06-16 CA CA3222350A patent/CA3222350A1/fr active Pending
- 2022-06-16 KR KR1020237043407A patent/KR20240032739A/ko unknown
- 2022-06-16 AU AU2022295088A patent/AU2022295088A1/en active Pending
- 2022-06-16 IL IL309237A patent/IL309237A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010105311A1 (fr) | 2009-03-20 | 2010-09-23 | Angioblast Systems, Inc. | Production de cellules pluripotentes reprogrammées |
WO2018096277A1 (fr) | 2016-11-23 | 2018-05-31 | Universite de Bordeaux | Microcompartiment cellulaire et procédés de préparation |
US20190330589A1 (en) * | 2016-11-23 | 2019-10-31 | Universite de Bordeaux | Cellular microcompartment and preparation processes |
US20200002681A1 (en) * | 2017-03-09 | 2020-01-02 | Universite de Bordeaux | Hollow cellular microfibre and method for producing such a hollow cellular microfibre |
WO2021028456A1 (fr) * | 2019-08-12 | 2021-02-18 | Treefrog Therapeutics | Unite tridimensionnelle creuse de tissu retinien et utilisation dans le traitement des retinopathies |
Non-Patent Citations (10)
Title |
---|
ACKERMANN JOSEPH ET AL: "Morpho-elasticity of human pluripotent stem cell cysts", JOURNAL OF THE MECHANICS AND PHYSICS OF SOLIDS, PERGAMON PRESS, OXFORD, GB, vol. 160, 29 January 2022 (2022-01-29), XP086958301, ISSN: 0022-5096, [retrieved on 20220129], DOI: 10.1016/J.JMPS.2022.104778 * |
ALESSANDR ET AL.: "A 3D printed microfluidic device for production offunctionalized hydrogel microcapsules for culture and differentiation of human Neuronal Stem Cells (hNSC", LAB ON A CHIP, vol. 16, no. 9, 2016, pages 1593 - 1604, XP055393107, DOI: 10.1039/C6LC00133E |
BAN ET AL.: "Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome", PROC JPN ACAD SER B PHYS BIOL SCI., vol. 85, no. 8, 2009, pages 348 - 62, XP002663242, DOI: 10.2183/PJAB.85.348 |
CHANG ET AL., CELL STEM CELL, vol. 2, no. 2, 2008, pages 113 - 117 |
KEVIN ALESSANDRI ET AL: "A 3D printed microfluidic device for production of functionalized hydrogel microcapsules for culture and differentiation of human Neuronal Stem Cells (hNSC)", LAB ON A CHIP, vol. 16, no. 9, 1 January 2016 (2016-01-01), UK, pages 1593 - 1604, XP055393107, ISSN: 1473-0197, DOI: 10.1039/C6LC00133E * |
NAKAGAWA ET AL., NAT BIOTECHNOL, vol. 26, no. 1, 2008, pages 101 - 106 |
TAKAHASHI ET AL.: "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", CELL, vol. 126, no. 5, 2006, pages 663 - 676 |
YEN-CHUN LU ET AL: "Designing compartmentalized hydrogel microparticles for cell encapsulation and scalable 3D cell culture", JOURNAL OF MATERIALS CHEMISTRY. B, vol. 3, no. 3, 27 December 2014 (2014-12-27), GB, pages 353 - 360, XP055660929, ISSN: 2050-750X, DOI: 10.1039/C4TB01735H * |
YU ET AL., SCIENCE, vol. 318, no. 5858, 2007, pages 1917 - 1920 |
ZHENG ET AL: "Controlled modelling of human epiblast and amnion development using stem cells", NATURE, vol. 573, 19 September 2019 (2019-09-19), pages 421, XP036888018, Retrieved from the Internet <URL:https://www.nature.com/articles/s41586-019-1535-2> [retrieved on 20220926] * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023235884A1 (fr) | 2022-06-03 | 2023-12-07 | Flagship Pioneering Innovations Vi, Llc | Compositions et méthodes |
Also Published As
Publication number | Publication date |
---|---|
US20240060025A1 (en) | 2024-02-22 |
JP2024521447A (ja) | 2024-05-31 |
IL309237A (en) | 2024-02-01 |
EP4355854A1 (fr) | 2024-04-24 |
AU2022295088A1 (en) | 2024-01-04 |
CA3222350A1 (fr) | 2022-12-22 |
KR20240032739A (ko) | 2024-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4223870A1 (fr) | Microcompartiment cellulaire et procédés de préparation | |
WO2022263601A1 (fr) | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes | |
WO2019224467A1 (fr) | Système de culture cellulaire en bioréacteur | |
WO2022238485A1 (fr) | Microcompartiments cellulaires comprenant des cellules dont l'intégrité génomique est maintenue apres amplification et procede de preparation | |
CA3147254A1 (fr) | Unite tridimensionnelle creuse de tissu retinien et utilisation dans le traitement des retinopathies | |
FR3124193A3 (fr) | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes | |
EP4214305A1 (fr) | Microcompartiments cellulaires comprenant des cellules humaines en cours de differenciation cardiaque, tissus obtenus a partir de ces microcompartiments et utilisations | |
EP4214306A1 (fr) | Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque | |
FR3134117A1 (fr) | Microcompartiments cellulaires comprenant des lymphocytes adaptés pour la culture à grande échelle | |
WO2024033284A1 (fr) | Substitut de matrice extracellulaire dans un microcompartiment cellulaire | |
FR3138661A1 (fr) | Substitut de matrice extracellulaire dans un microcompartiment cellulaire | |
WO2024105130A1 (fr) | Substitut de matrice extracellulaire dans un microcompartiment cellulaire | |
WO2023194479A1 (fr) | Microcompartiments cellulaires comprenant des lymphocytes formant une culture groupee en 3d et ayant une faible teneur en granzyme b | |
FR3134114A1 (fr) | Microcompartiments cellulaires comprenant des lymphocytes adaptés pour la culture à grande échelle | |
FR3134115A1 (fr) | Microcompartiments cellulaires comprenant des lymphocytes formant une culture groupée en 3D et ayant une faible teneur en granzyme B | |
WO2023214055A1 (fr) | Microtissu hepatique particulier en trois dimensions et utilisations dans le traitement de l'insuffisance hepathique | |
FR3135279A1 (fr) | Microtissu hépatique particulier et utilisations dans le traitement de l’insuffisance hépatique | |
FR3135278A1 (fr) | Microtissu hépatique particulier et utilisations dans le traitement de l’insuffisance hépatique | |
EP3994249A1 (fr) | Procede de production in vitro de neurones de mammiferes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22735136 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18270931 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 309237 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2023576139 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3222350 Country of ref document: CA Ref document number: 2022295088 Country of ref document: AU Ref document number: AU2022295088 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 806532 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202393220 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/015371 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2022295088 Country of ref document: AU Date of ref document: 20220616 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022735136 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022735136 Country of ref document: EP Effective date: 20240116 |